DGAP-News: STRATEC Biomedical AG / Key word(s): Takeover/Acquisition STRATEC completes acquisition of Sony DADC BioSciences 01.07.2016 / 11:38 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- PRESS RELEASE STRATEC completes acquisition of Sony DADC BioSciences Birkenfeld, July 1, 2016 STRATEC Biomedical AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard, TecDAX) today announces the successful completion of the acquisition of Sony DADC BioSciences GmbH ("BioSciences"), a leading global OEM supplier of smart consumables for diagnostics, life sciences and medical technology applications. On June 8, 2016, STRATEC announced that it signed an agreement with Sony DADC Austria AG ("Sony DADC"), based in Anif/Salzburg, Austria, to acquire all of the shares of BioSciences, a wholly-owned subsidiary of Sony DADC. The joining of these companies will enlarge STRATEC's capabilities to serve its customers, by combining macro-and microfluidic solutions as well as offering services spanning sample preparation solutions, software, instrument automation and polymer consumables development and manufacturing. The acquisition diversifies STRATEC's overall customer structure and extends the value chain significantly. Going forward, the business will operate under the name of STRATEC Consumables. The consolidation will start with July, 1, 2016. About STRATEC STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. Furthermore, the company offers sample preparation solutions, integrated laboratory software, and complex consumables for diagnostic and medical applications. STRATEC covers the entire value chain - from development to design and production through to quality assurance. The partners market the systems, software and consumables in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange. Further information can be obtained from: STRATEC Biomedical AG Sandra Eberle, Investor Relations Gewerbestr. 37, 75217 Birkenfeld Germany Phone: +49 7082 7916-197 Fax: +49 7082 7916-999 [email protected] www.stratec.com STRATEC Consumables Ricarda Pichler, Marketing Sonystr. 20, A-5081 Anif/Salzburg Austria Phone: +43 6246 880 8142 Fax: +43 6246 880 9187 [email protected] www.consumables.stratec.com --------------------------------------------------------------------------- 01.07.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: STRATEC Biomedical AG Gewerbestr. 37 75217 Birkenfeld Germany Phone: +49 (0)7082 7916 0 Fax: +49 (0)7082 7916 999 E-mail: [email protected] Internet: www.stratec.com ISIN: DE000STRA555 WKN: STRA55 Indices: TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Terminbörse EUREX End of News DGAP News Service --------------------------------------------------------------------------- 476469 01.07.2016